TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In a randomized controlled trial led by the University of Surrey, 61 participants took NOVOS Core or a placebo daily for six months. The supplement group showed favorable changes in endothelial function, arterial stiffness and systolic blood pressure, but the study did not assess cardiovascular events or longer-term health benefits.
A randomized controlled trial led by the University of Surrey found that participants taking the multi-component supplement NOVOS Core for six months had favorable changes in endothelial function, arterial stiffness and systolic blood pressure compared with a placebo group. The 61-person study measured cardiovascular biomarkers, not heart attacks, strokes or other clinical outcomes, so it does not establish that the supplement prevents disease.
The trial included 33 people assigned to the supplement and 28 assigned to a placebo. Participants took their assigned product once daily for six months. Researchers also measured some vascular responses shortly after the first dose. They reported improved flow-mediated dilation, a measure of how well blood vessels respond to increased blood flow, within one hour in the supplement group; readings in the control group remained largely unchanged.
At six months, the adjusted difference between groups in systolic blood pressure was 6.1 mmHg in favor of the supplement. Pulse wave velocity, a measure of arterial stiffness, was also lower in the supplement group, with an adjusted between-group difference of 1.18 m/s. The researchers said these measures reflect related but distinct aspects of vascular health and are associated with cardiovascular risk.
Blood tests showed no significant change in cholesterol or other blood lipids, according to the report. The estimated 10-year cardiovascular risk declined modestly, largely reflecting the systolic blood pressure difference. The study was published in European Heart Journal Open as “Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial.”
What the Vascular Changes Show
The findings offer early human evidence that a supplement combining vitamins and minerals, amino acids and plant-derived bioactives may affect several vascular measurements. The research team designed the formulation around biological processes associated with aging, rather than focusing on a single nutrient or pathway. The results may help guide further research into whether targeting multiple processes at once can influence cardiovascular biomarkers.
The blood pressure result may appear meaningful because prior large studies have associated a sustained 5 mmHg reduction in systolic pressure with about a 10% reduction in major cardiovascular events. That comparison is background from other research, not an outcome demonstrated in this trial. The trial lasted six months and was not designed to determine whether participants experienced fewer cardiovascular events. Its marker changes cannot be treated as proof of a health benefit for individuals.
Products Worth Considering
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes and Travel Case, White
As an affiliate, we earn on qualifying purchases.
Testing an Aging Biology Approach
The study examined the idea that biological aging involves multiple interacting processes and that addressing several at once might affect body systems influenced by aging. NOVOS Core was developed around that rationale, according to Diogo Barardo, the company’s director of research and development. The trial tested vascular measurements as an initial step, rather than testing whether the product changes aging itself or prevents age-related disease.
Professor Christian Heiss of the University of Surrey said the researchers chose established measures such as blood pressure and cholesterol before attempting to assess clinical outcomes. The study’s title and report describe both acute and six-month effects. Its results concern this particular formulation and trial population; they should not be generalized to other supplements or assumed to apply to everyone.
“We now need larger studies to understand the mechanisms involved and, importantly, whether these changes translate into longer-term health benefits.”
— Christian Heiss, professor of cardiovascular medicine at the University of Surrey
Clinical Benefits Still Unproven
The trial does not establish whether the reported changes persist after participants stop taking the supplement, or whether they lead to fewer heart attacks, strokes or deaths. It also cannot show from the reported results which ingredients, if any, drove the changes, or how the components may have interacted. The modest sample of 61 participants limits how confidently the findings can be applied to wider populations.
The report does not establish the supplement’s effects across different age groups, health conditions or medication use. While estimated cardiovascular risk decreased modestly, that estimate was driven largely by the blood pressure difference and is not the same as observing fewer events. Larger and longer studies are needed to confirm the findings, examine mechanisms and assess safety and clinical outcomes.
Larger Trials Needed to Confirm Findings
The researchers say the next research steps are to test the results in larger studies, investigate the biological mechanisms and determine whether the marker changes translate into longer-term health benefits. The available report does not specify a timeline or announce a follow-up trial. Until such evidence is available, the study supports further investigation rather than a conclusion that NOVOS Core prevents cardiovascular disease.
Key Questions
What did the trial find?
The 61-person trial reported favorable changes in endothelial function, arterial stiffness and systolic blood pressure after six months among participants assigned to NOVOS Core compared with placebo.Did the study show that the supplement prevents heart attacks or strokes?
No. The trial assessed vascular biomarkers and was not designed to measure heart attacks, strokes or other clinical outcomes.How large was the blood pressure difference?
At six months, the adjusted between-group difference in systolic blood pressure was 6.1 mmHg in favor of the supplement group. The finding does not by itself establish a lasting effect or a reduction in cardiovascular events.Did cholesterol levels change?
Researchers reported no significant changes in cholesterol or other blood lipids in blood tests.What research is needed next?
The researchers called for larger studies to confirm the results, examine how the supplement may affect vascular function and test whether marker changes correspond to longer-term health benefits.Source: news-medical.net
